Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 10 |
| List of Tables | 9 | 3 |
| List of Figures | 12 | 3 |
| Gastrointestinal Disorders Therapeutics Market - Introduction | 15 | 1 |
| Overview | 15 | 1 |
| Global Gastrointestinal Disorders Therapeutics Market - Market Characterization | 16 | 8 |
| Market Forecasts | 16 | 2 |
| Branded and Generic Global Market Share | 18 | 1 |
| Annual Cost of Treatment | 19 | 1 |
| Treatment Usage Patterns | 20 | 1 |
| Diseased Population | 21 | 1 |
| Diagnosed Population | 21 | 1 |
| Prescription Population | 21 | 1 |
| Drivers and Restraints for the Global Gastrointestinal Disorders Therapeutics Market | 22 | 1 |
| Market Drivers | 22 | 1 |
| Increase in the Prevalence Rate and Aging Population | 22 | 1 |
| Increase in Awareness of Disease Progression and Etiology | 22 | 1 |
| New Drug Launches in the Near Future | 22 | 1 |
| Market Restraints | 23 | 1 |
| Patent Expiries of Major Drugs and the Entry and Dominance of Generics in the Future | 23 | 1 |
| Low Diagnosis Rate | 23 | 1 |
| Serious Side Effects Associated with Certain Classes of Drugs | 23 | 1 |
| Gastrointestinal Disorders Therapeutics Market - Geographical Landscape | 24 | 22 |
| Revenue Analysis by Geography | 24 | 1 |
| The US | 24 | 1 |
| Revenue | 24 | 2 |
| Annual Cost of Treatment | 26 | 1 |
| Treatment Usage Patterns | 27 | 1 |
| Diseased Population | 28 | 1 |
| Diagnosed Population | 28 | 1 |
| Prescription Population | 28 | 1 |
| Top Five Countries of Europe | 29 | 1 |
| Revenue | 29 | 1 |
| Revenue by Country | 30 | 2 |
| Annual Cost of Treatment | 32 | 1 |
| Treatment Usage Patterns | 33 | 1 |
| Diseased Population | 34 | 1 |
| Diagnosed Population | 34 | 1 |
| Prescription Population | 34 | 1 |
| Japan | 35 | 1 |
| Revenue | 35 | 2 |
| Annual Cost of Treatment | 37 | 1 |
| Treatment Usage Patterns | 38 | 1 |
| Diseased Population | 39 | 1 |
| Diagnosed Population | 39 | 1 |
| Prescription Population | 39 | 1 |
| Gastrointestinal Disorders Therapeutics Market India-Overview | 40 | 1 |
| Epidemiology | 40 | 1 |
| Clinical Trials | 41 | 1 |
| Drivers and Restraints | 41 | 1 |
| Gastrointestinal Disorders Therapeutics Market Australia-Overview | 42 | 1 |
| Epidemiology | 42 | 1 |
| Clinical Trials | 43 | 1 |
| Drivers and Restraints | 43 | 1 |
| Gastrointestinal Disorders Therapeutics Market China-Overview | 44 | 1 |
| Epidemiology | 44 | 1 |
| Clinical Trials | 45 | 1 |
| Drivers and Restraints | 45 | 1 |
| Global Gastrointestinal Disorders Therapeutics Market - Therapeutic Landscape | 46 | 63 |
| Global Irritable Bowel Syndrome Therapeutics Market Forecasts | 46 | 1 |
| Introduction | 46 | 1 |
| Treatment Flow Algorithm | 47 | 1 |
| Revenue | 48 | 1 |
| Revenue by Country | 49 | 2 |
| Branded vs. Generic Market Share | 51 | 1 |
| Annual Cost of Treatment | 52 | 1 |
| Treatment Usage Patterns | 53 | 1 |
| Diseased Population | 54 | 1 |
| Diagnosed Population | 54 | 1 |
| Prescription Population | 54 | 1 |
| Drivers and Restraints for the Irritable Bowel Syndrome Therapeutics Market | 55 | 1 |
| Drivers for the Irritable Bowel Syndrome Therapeutics Market | 55 | 1 |
| Launch of New Drugs with Novel Mechanisms of Action | 55 | 1 |
| High Prevalence and Significant Unmet Need Makes the Market More Attractive | 55 | 1 |
| Restraints for the Irritable Bowel Syndrome Therapeutics Market | 55 | 1 |
| Low Diagnosis and Prescription Rate Reduces the Number of Patients Receiving Treatment | 55 | 1 |
| Lack of Definite Diagnostic Techniques Delays Treatments | 55 | 1 |
| Global Constipation Therapeutics Market Forecasts | 56 | 1 |
| Introduction | 56 | 1 |
| Treatment Flow Algorithm | 57 | 1 |
| Revenue | 58 | 1 |
| Revenue Analysis by Country | 59 | 2 |
| Branded vs. Generic Market Share | 61 | 1 |
| Annual Cost of Treatment | 62 | 1 |
| Treatment Usage Patterns | 63 | 1 |
| Diseased Population | 64 | 1 |
| Diagnosed Population | 64 | 1 |
| Prescription Population | 64 | 1 |
| Drivers and Restraints for the Constipation Therapeutics Market | 65 | 1 |
| Drivers for Constipation Therapeutics Market | 65 | 1 |
| Launch of New Drugs with Novel Mechanism of Action will Drive Market Growth | 65 | 1 |
| Significant Unmet Need and Strong Commercial Opportunities Renders the Market More Attractive | 65 | 1 |
| Restraints for Constipation Therapeutics Market | 65 | 1 |
| Low Treatment-seeking and Diagnosis Rates Hinder Growth | 65 | 1 |
| Global Crohn s Disease Therapeutics Market Forecasts | 66 | 1 |
| Introduction | 66 | 1 |
| Treatment Flow Algorithm | 67 | 1 |
| Revenue | 68 | 1 |
| Revenue by Country | 69 | 2 |
| Branded vs. Generic Market Share | 71 | 1 |
| Annual Cost of Treatment | 72 | 1 |
| Treatment Usage Patterns | 73 | 1 |
| Diseased Population | 74 | 1 |
| Diagnosed Population | 74 | 1 |
| Prescription Population | 74 | 1 |
| Drivers and Restraints for the Crohn s Disease Therapeutics Market | 75 | 1 |
| Drivers for the Crohn s Disease Therapeutics Market | 75 | 1 |
| Increasing Prevalence of Crohn s Disease | 75 | 1 |
| Existing High-priced Biological Drugs and Future Approval of More Biologics to Fuel Market Growth | 75 | 1 |
| Restraints for the Crohn s Disease Therapeutics Market | 75 | 1 |
| Low Diagnosis Rate Acts as a Barrier for the Market | 75 | 1 |
| Global Ulcerative Colitis Therapeutics Market Forecasts | 76 | 1 |
| Introduction | 76 | 1 |
| Treatment Flow Algorithm | 77 | 1 |
| Revenue | 78 | 1 |
| Revenue by Country | 79 | 2 |
| Branded vs. Generic Market Share | 81 | 1 |
| Annual Cost of Treatment | 82 | 1 |
| Treatment Usage Patterns | 83 | 1 |
| Diseased Population | 84 | 1 |
| Diagnosed Population | 84 | 1 |
| Prescription Population | 84 | 1 |
| Drivers and Restraints for the Ulcerative Colitis Therapeutics Market | 85 | 1 |
| Drivers for the Ulcerative Colitis Therapeutics Market | 85 | 1 |
| Future Approval of Biologics will Drive the Market | 85 | 1 |
| Availability of Large Patient Pool will Increase the Market Revenue | 85 | 1 |
| Restraints for the Ulcerative Colitis Therapeutics Market | 85 | 1 |
| Diagnostic Limitations could Affect Market Growth | 85 | 1 |
| Complex Etiology of Ulcerative Colitis Makes Diagnosis and Treatment Difficult | 85 | 1 |
| Global Gastroesophageal Reflux Disease Therapeutics Market Forecasts | 86 | 1 |
| Introduction | 86 | 1 |
| Treatment Flow Algorithm | 87 | 2 |
| Revenue | 89 | 2 |
| Revenue by Country | 91 | 2 |
| Branded vs. Generic Market Share | 93 | 1 |
| Annual Cost of Treatment | 94 | 1 |
| Treatment Usage Patterns | 95 | 1 |
| Diseased Population | 96 | 1 |
| Diagnosed Population | 96 | 1 |
| Prescription Population | 96 | 1 |
| Drivers and Restraints for the Gastroesophageal Reflux Disease Therapeutics Market | 97 | 1 |
| Drivers for the Gastroesophageal Reflux Disease Therapeutics Market | 97 | 1 |
| Increase in Diseased and Prescription Populations Drives the Market | 97 | 1 |
| Restraints for the Gastroesophageal Reflux Disease Therapeutics Market | 97 | 1 |
| Declining Annual Cost of Treatment will Obstruct Market Growth | 97 | 1 |
| Low Unmet Need Makes the Market Less Attractive | 97 | 1 |
| Global Peptic Ulcer Disease Therapeutics Market Forecasts | 98 | 1 |
| Introduction | 98 | 1 |
| Treatment Flow Algorithm | 99 | 1 |
| Revenue | 100 | 2 |
| Revenue Analysis by Country | 102 | 2 |
| Generic vs. Branded Market Share | 104 | 1 |
| Annual Cost of Treatment | 105 | 1 |
| Treatment Usage Patterns | 106 | 1 |
| Diseased Population | 107 | 1 |
| Diagnosed Population | 107 | 1 |
| Prescription Population | 107 | 1 |
| Drivers and Restraints for the Peptic Ulcer Disease Therapeutics Market | 108 | 1 |
| Drivers for Peptic Ulcer Disease Therapeutics Market | 108 | 1 |
| Increase in Diseased, Diagnosed and Prescription Populations to Drive the Market | 108 | 1 |
| Launch of New Formulations and Combination Products to Drive the Market | 108 | 1 |
| Restraints for Peptic Ulcer Disease Therapeutics Market | 108 | 1 |
| Patent Expiries of Proton Pump Inhibitors will Slow Market Growth | 108 | 1 |
| Low Unmet Need Makes the Market Less Attractive | 108 | 1 |
| Global Gastrointestinal Disorders Therapeutics Market - Pipeline Analysis | 109 | 22 |
| Summary | 109 | 1 |
| Research and Development Pipeline by Phase | 109 | 1 |
| Research and Development Pipeline by Indication | 110 | 1 |
| Irritable Bowel Syndrome: Research and Development Pipeline | 111 | 1 |
| Pipeline by Phase | 111 | 1 |
| Constipation: Research and Development Pipeline | 112 | 1 |
| Research and Development Pipeline by Phase | 112 | 1 |
| Crohn s Disease: Research and Development Pipeline | 113 | 1 |
| Research and Development Pipeline by Phase | 113 | 1 |
| Ulcerative Colitis: Research and Development Pipeline | 114 | 1 |
| Research and Development Pipeline by Phase | 114 | 1 |
| Gastroesophageal Reflux Disease: Research and Development Pipeline | 115 | 1 |
| Research and Development Pipeline by Phase | 115 | 1 |
| Peptic Ulcer Disease: Research and Development Pipeline | 116 | 1 |
| Research and Development Pipeline by Phase | 116 | 1 |
| Promising Pipeline Molecules | 117 | 1 |
| Linzess (linaclotide) | 118 | 1 |
| Overview | 118 | 1 |
| Indications | 118 | 1 |
| Clinical Trial Data | 118 | 2 |
| Approved Date | 120 | 1 |
| Views | 120 | 1 |
| Xifaxan (rifaximin) | 120 | 1 |
| Overview | 120 | 1 |
| Indications: | 120 | 1 |
| Clinical Trial Data | 120 | 1 |
| Likelihood of Receiving Approval and Timeline | 121 | 1 |
| Views | 121 | 1 |
| Relistor (methylnaltrexone) | 121 | 1 |
| Overview | 121 | 1 |
| Indication | 121 | 1 |
| Clinical Trial Data | 122 | 1 |
| Likelihood of Receiving Approval and Timeline | 122 | 1 |
| Views | 122 | 1 |
| Humira (adalimumab) | 123 | 1 |
| Overview | 123 | 1 |
| Indications | 123 | 1 |
| Clinical Trial Data | 123 | 1 |
| Likelihood of Receiving Approval and Timeline | 123 | 1 |
| Views | 123 | 1 |
| Uceris (budesonide) | 123 | 1 |
| Overview | 123 | 1 |
| Indications | 124 | 1 |
| Clinical Trial Data | 124 | 1 |
| Likelihood of Receiving Approval and Timeline | 124 | 1 |
| Views | 124 | 1 |
| Plecanatide | 124 | 1 |
| Overview | 124 | 1 |
| Indications | 124 | 1 |
| Clinical Trial Data | 124 | 1 |
| Likelihood of Receiving Approval and Timeline | 125 | 1 |
| Views | 125 | 1 |
| Vedolizumab (MLN0002) | 125 | 1 |
| Overview | 125 | 1 |
| Indications | 125 | 1 |
| Clinical Trial Data | 125 | 1 |
| Likelihood of Receiving Approval and Timeline | 126 | 1 |
| Views | 126 | 1 |
| Naloxegol (NKTR-118) | 126 | 1 |
| Overview | 126 | 1 |
| Indication | 126 | 1 |
| Clinical Trial Data | 126 | 1 |
| Likelihood of Receiving Approval and Timeline | 127 | 1 |
| Views | 127 | 1 |
| Simponi (golimumab) | 127 | 1 |
| Overview | 127 | 1 |
| Indication | 127 | 1 |
| Clinical Trial Data | 127 | 1 |
| Likelihood of Receiving Approval and Timeline | 127 | 1 |
| Views | 127 | 1 |
| Asimadoline | 128 | 1 |
| Overview | 128 | 1 |
| Indication | 128 | 1 |
| Clinical Trial Data | 128 | 1 |
| Likelihood of Receiving Approval and Timeline | 129 | 1 |
| Views | 129 | 1 |
| Traficet-EN (GSK-1605786) | 129 | 1 |
| Overview | 129 | 1 |
| Indication | 129 | 1 |
| Clinical Trial Data | 129 | 1 |
| Likelihood of Receiving Approval and Timeline | 130 | 1 |
| Views | 130 | 1 |
| Cobiprostone | 130 | 1 |
| Overview | 130 | 1 |
| Indication | 130 | 1 |